Albireo Provides First Quarter 2018 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
May 17, 2018 7:31 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($0.15), versus $1.77 reported last year. Revenue for the quarter came in at $11.2 million versus the consensus estimate of $31.32 million.
The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and Chief Executive... More
